ArticleJournal of pharmaceutical health care and sciences2026
Therapeutic drug monitoring of intravenous amikacin during peritoneal dialysis for Mycobacterium abscessus exit-site infection: a case report.
Article in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with peritoneal dialysis (PD) often develop exit-site infections (ESI) caused by nontuberculous mycobacteria. Antimicrobial therapy, including intravenous amikacin (AMK), is combined with PD catheter removal to control the source of infection. However, the efficiency of AMK removal using PD remains unclear. In this report, we describe AMK pharmacokinetics before and after PD catheter removal in a patient diagnosed with Mycobacterium abscessus from ESI. CASE PRESENTATION: A 73-year-old female PD patient weighing 42.4 kg who received intravenous AMK + clarithromycin + imipenem/cilastatin for Mycobacterium abscessus ESI on day 1 under therapeutic drug monitoring. During hospitalization, the patient underwent a typical PD regimen including nocturnal continuous ambulatory PD with Reguneal HCa 1.5
conclusionsThe effect of PD on AMK concentration was limited during therapeutic drug monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.